Nuvalent, Inc. (NASDAQ: NUVL) reported an insider transaction on April 9, 2026, when Chief Scientific Officer Henry E. Pelish sold 3,093 shares of the company's Class A Common Stock. The block of shares was disposed of at prices between $104.27 and $105.00, producing proceeds of $323,164.
On that same date, Pelish exercised stock options to acquire 3,093 shares of Class A Common Stock at an exercise price of $27.85 per share, representing an outlay of $86,140. After completing both the sale and the option exercise, Pelish's direct ownership in Nuvalent stands at 65,604 shares.
These transactions arrive while Nuvalent's stock has appreciated materially over the past year, with a reported year-over-year gain of 55%. At the same time, analysis from InvestingPro indicates the share price is trading above its Fair Value estimate.
Operationally and financially, Nuvalent disclosed a fourth-quarter net loss of $118.7 million and a full-year 2025 net loss of $425.4 million. The company has been active on the regulatory front: the U.S. Food and Drug Administration accepted Nuvalent's New Drug Application for zidesamtinib, a drug candidate for ROS1-positive non-small cell lung cancer, and assigned a PDUFA target action date of September 18, 2026.
Nuvalent also submitted a New Drug Application for neladalkib, which targets advanced ALK-positive non-small cell lung cancer in patients previously treated with tyrosine kinase inhibitors. Those filings are central to the company's near-term clinical and commercial milestones.
Market commentary and analyst coverage referenced in filings and reports highlight differing perspectives. Stifel reiterated a Buy rating on Nuvalent and kept a price target of $135.00, pointing to management's confidence about the forthcoming ROS1 launch. Wells Fargo initiated coverage with an overweight rating and a $116.00 price target, citing optimism about the commercial potential of zidesamtinib and the safety profile reported for neladalkib.
Additional context from InvestingPro flagged that Nuvalent's balance sheet contains more cash than debt, noted as one of 11 tips offered to subscribers. That point, alongside the company's reported losses and pending regulatory decisions, frames the current investor and analyst discussion around funding runway, commercialization timing, and valuation.
Pelish's sale and simultaneous option exercise represent concrete moves by a senior executive but do not, on their own, change the public facts about Nuvalent's clinical programs, financial results, or analyst views. Shareholders and observers will likely continue to watch regulatory timelines, clinical-readout progress, and any further insider activity for additional signals.